Skip to main content

Table 4 Systemic treatment at baseline according to anatomic and clinical classifications of autoimmune uveitis (AU)

From: Autoimmune uveitis: a retrospective analysis of 104 patients from a tertiary reference center

Treatment at baseline Total number(104 pts) Anterior autoimmune uveitis(48 pts) Intermediate autoimmune uveitis(5 pts) Posterior autoimmune uveitis(45 pts) Panuveitis(6 pts) Idiopathic autoimmune uveitis(75 pts) Systemic disease-associated autoimmune uveitis(29 pts)
Corticosteroids 5 (4.8%) 4 (80%) 1 (20%) 0 (0%) 0 (0%) 4 (80%) 1 (20%)
Corticosteroids + Azathioprine 36 (34.6%) 31 (86.1%) 1 (2.7%) 4 (11.1%) 0 (0.0%) 24 (66.6%) 12 (33.3%)
Corticosteroids + Cyclosporine-A 35 (33.6%) 9 (25.7%) 2 (5.7%) 24 (68.5%) 0 (0%) 29 (82.8%) 6 (17.1%)
Corticosteroids + Cyclophosphamide 8 (7.6%) 0 (0%) 0 (0%) 7 (87.5%) 1 (12.5%) 6 (75%) 2 (25%)
Corticosteroids + Methotrexate 2 (1.9%) 1 (50%) 0 (0%) 1 (50%) 0 (0%) 0 (0%) 2 (100%)
Corticosteroids + Combined immunosuppressive therapy 18 (17.3%) 3 (16.6%) 1 (5.5%) 9 (50%)a 5 (27.7%) 12 (66.6%) 6 (33.3%)
  1. aIn three patients, corticosteroids were given as an FDA-approved dexamethasone intravitreal implant.